This is the authors' abstract. We don't add key points for this paper.
Immune checkpoint inhibitors have become standard-of-care for the treatment of NSCLC; however, their use brings with it the risk of a unique set of inflammatory side effects, termed immune-related adverse events (irAEs). The recognition, diagnosis, and management of irAEs have become essential to clinical practice, with the potential for high-grade toxicities affecting treatment decision-making. This manuscript provides a state-of-the-art review of irAEs as they pertain to patients with NSCLC, by summarizing the common and severe toxicities of the standard immune checkpoint inhibitor regimens and clinical treatment settings relevant to this disease and future directions.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Pierce et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: